Arkolith/Insider Trading/ELDN/Form 4

Gros David-Alexandre C

Chief Executive Officer, DirectorEledon Pharmaceuticals, Inc. (ELDN) · full profile →Form 4 · filed Feb 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2023Grant(A)300K—$0300K
Feb 1, 2023Grant(A)154K—$0154K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-006324) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML